online only

13 Houston energy tech startups pitch at Rice Alliance's first virtual event

The show had to go on at the annual Energy Tech Venture Day, which was put on virtually by the Rice Alliance on May 7. Zukiman Mohamad/Pexels

Rice Alliance for Technology and Entrepreneurship's annual Energy Tech Venture Day is usually hosted as a part of the Offshore Technology Conference that takes over NRG Center each May. However, when OTC announced its cancelation, Rice Alliance made sure the show would go on.

"We had many startups and corporations reach out to us and ask us if we could go ahead with the event in a virtual format, so that's how we ended up where we are today," says Brad Burke, managing director of the Rice Alliance at the start of the event.

Throughout the two-hour pitch event, 39 startups pitched their companies in two minutes and 30 seconds or less. The companies were selected based on input from the alliance's energy advisory board. The companies, Burke says, represent innovations across the energy industry.

An additional 24 companies participated in virtual office hours with investors through a speed-networking process.

"We know that the needs of startups to raise capital, to find customers, and to find pilots is even greater today than it was several months ago," Burke says. "And we know that the needs of energy companies to find innovative technologies to reduce costs and increase production are even greater as well."

Usually at this event, the advisory board decides on the 10 most promising energy tech startups, however, this list will not be revealed this year.

Of the startups that pitched that represented 11 different states and six different countries, 13 call Houston their HQ. Here's what local startups pitched.

Bluware

Bluware's E&P clients use the startup's cloud computing and deep learning technology to access seismic data. This data is crucial for geoscientists to make faster and smarter decisions to reduce time to oil. Bluware's headquarters is in West Houston, and has an European office in Norway.

DAMorphe

Southwest Houston-based DAMorphe uses nanotechnology to provide solutions within oil and gas ā€” among other sectors, including life sciences, consumer goods, and more. Within O&G specifically, the company has designed dissolvable frac plugs and balls with superior performance and lower cost, as well as a flowable sensor for downhole measurements.

dataVediK

Early-stage Houston startup dataVediK focusing on enterprise digital transformation with a plan to create an artificial intelligence platform for collaboration between data scientists and domain experts to provide tech solutions for oil and gas ā€” such as optimizing operations costs and productivity, enhancing safety, and more.

DelfinSia

Houston-based Delfin specializes in text analytics and is working with two oil supermajors. Sia, Delfin's product, is a virtual adviser, able to reference a client's unstructured data in real-time to ensure that decisions are fully informed. Users can simply ask Sia a question and get the best answers from company data.

Flutura Decision Sciences and Analytics

Flutura's motto is to promote actions ā€” not just insights with data. The company's main product is Cerebra uses artificial intelligence and industrial internet of things to connect the dots within the oil and gas supply chain. Flutura's clients include Shell, Honeywell, Henkel, TechnipFMC, Patterson UTI, ABB, BJ Services, Daimler Benz, and more.

MyPass Global

A workforce management system, MyPass Global is putting the power of data into the hands of the individual workers at oil and gas companies and is creating digital work skills passport for each employee. The startup has developed a network of over 180 business partners across Australia, New Zealand, and the United States, which includes more than 27,000 registered workers.

Nomad Proppant Services

For E&P companies, Nomad is revolutionizing the way sand is delivered and used by wells. The average well uses 10,000 tons of sand, and that means trucking that volume via long hauls. However, Nomad has created a new, mobile mine that can save 25 percent of the company's spend on sand.

Osperity

Houston-based Osperity's technology provides AI-driven intelligent visual monitoring for industrial operations that can result in improved safety, reduced carbon footprints, and more. The company has more than 40 industrial customers using its monitoring services. Osperity offices in the Galleria area and has a location in Calgary.

PhDsoft Technology

PhDsoft, an engineering technology company, has created a technology specializing in industrial digital twins. The company's 4D software, PhDC4DĀ®, can predict the effect of time and elements on equipment and facilities, which can save its industrial clients money and downtime of its machinery, as well as improve safety conditions.

Quidnet Energy

Clean energy tech company, Quidnet Energy, is providing electricity storage solutions that are cost effective and are able to be used long term. Quidnet uses traditional pumped hydro storage that, before the company, was restricted to specific terrains. The company offices out of downtown Houston.

SOTAOG

Data analytics company SOTAOG wants to be one-stop shop for its energy clients' data needs. SOTAOG's proprietary algorithms can provide real-time data that can improve operations and create cost-saving initiatives. The company works out of The Cannon's West Houston campus.

Voyager

Houston-based software startup Voyager is making waves in the maritime bulk-shipping industry. Whether shipping plans are transporting crude oil and LNG or complex offshore rig movements, Voyager can replace the thousands of logistics emails shared across several companies and bring communications and data onto one platform. The company's main office is in downtown Houston, but also has an office in Brazil.

WellNoz

WellNoz creates inflow control devices, or ICDs, for its oil and gas industry clients. The downhole devices are crucial for controlling the opening and closing of the well. WellNoz's device is made from a proprietary metal alloy that remains strong to remain closed when required, and then dissolves after a certain time to open up the valve. The startup's first client is Abu Dhabi National Oil Company, which will will purchase 10,000 ICDs each year for the next five years.

Trending News

Building Houston

 
 

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News